Charles River Laboratories
638 hedge funds and large institutions have $17.6B invested in Charles River Laboratories in 2021 Q2 according to their latest regulatory filings, with 126 funds opening new positions, 216 increasing their positions, 220 reducing their positions, and 46 closing their positions.
174% more first-time investments, than exits
New positions opened: 126 | Existing positions closed: 46
29% more capital invested
Capital invested by funds: $13.6B → $17.6B (+$3.95B)
14% more funds holding
Funds holding: 561 → 638 (+77)
0.07% less ownership
Funds ownership: 94.73% → 94.66% (-0.07%)
1% less call options, than puts
Call options by funds: $84.3M | Put options by funds: $85.5M
2% less repeat investments, than reductions
Existing positions increased: 216 | Existing positions reduced: 220
6% less funds holding in top 10
Funds holding in top 10: 17 → 16 (-1)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$252M |
| 2 |
State Street
Boston,
Massachusetts
|
+$250M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$176M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$110M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$95.5M |
Top Sellers
| 1 |
BlackRock
New York
|
-$219M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$212M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$76.1M |
| 4 |
EIP
Epoch Investment Partners
New York
|
-$73.1M |
| 5 |
AI
Ariel Investments
Chicago,
Illinois
|
-$63.4M |
CRL Hedge Fund Activity: Q2 2021 in Review
638 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q2 2021, worth a combined $17.6B — up 29% from $13.6B a quarter earlier.
Buyers outnumbered sellers: 126 funds opened new CRL positions and 46 closed out — a net gain of 80 holders — while 216 added to existing stakes and 220 trimmed.
The largest buyer was Vanguard Group, adding an estimated $252M. The largest seller was BlackRock, cutting an estimated $219M.
- 638 institutional investors held Charles River Laboratories (CRL) as of Q2 2021, up from 561 in Q1 2021.
- Funds reported $17.6B of Charles River Laboratories stock for Q2 2021, up 29% quarter-over-quarter.
- 126 funds opened new Charles River Laboratories positions in Q2 2021 and 46 closed out, a net change of +80 holders.
- The largest Charles River Laboratories buyer in Q2 2021 was Vanguard Group, an estimated $252M added.
- The largest Charles River Laboratories seller in Q2 2021 was BlackRock, an estimated $219M sold.
Based on aggregated 13F filings for Q2 2021.